<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00140582</url>
  </required_header>
  <id_info>
    <org_study_id>PRIMA</org_study_id>
    <nct_id>NCT00140582</nct_id>
  </id_info>
  <brief_title>Primary Rituximab and Maintenance</brief_title>
  <official_title>Advanced Follicular Lymphoma Evaluating the Benefit of Maintenance Therapy With Rituximab (MabThera®) After Induction of Response With Chemotherapy Plus Rituximab in Comparison With no Maintenance Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lymphoma Study Association</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HOVON - Dutch Haemato-Oncology Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Low Grade Lymphoma Study Group (GLSG/OSHO)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Australasian Leukaemia and Lymphoma Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lymphoma Study Association</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Objectives

             -  Primary objective: To evaluate in patients with advanced follicular lymphoma the
                benefit of maintenance therapy with rituximab after induction of response with
                chemotherapy plus rituximab in comparison with no maintenance therapy

             -  Secondary objective: To evaluate response rates, event driven survival endpoints
                (EFS, PFS, OS) and quality of life of four different chemotherapy regimens combined
                with rituximab, with or without maintenance with rituximab, for first line
                treatment of advanced stage follicular lymphoma.

        -  Study Design This is an international open-label, multicentre, randomized study with two
           treatment phases. In the induction phase patients have to respond to 1st line induction
           treatment in order to be eligible for randomization to the second phase of maintenance
           treatment or observation. After the maintenance period patients will be included in the
           follow up phase for 3 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study medication

        -  First period: Induction of response with 8 x rituximab combined with 8 cycles of CVP or
           6 cycles of CHOP in 21-day cycles or 6 cycles of FCM in 28-day cycles or 6 cycles of MCP
           in 28-day cycles.

        -  Second period: rituximab 375 mg/m2 every 8 weeks for 24 months (12 injections) or
           control with no treatment
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2004</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>number of event observed driven : 344 events or 10 years</time_frame>
    <description>defined as the time from randomization to progression, relapse, death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rates, event driven survival endpoints (EFS, PFS, OS)</measure>
    <time_frame>number of event observed driven : 344 events or 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>number of event observed driven : 344 events or 10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1217</enrollment>
  <condition>Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>A : rituximab maintenance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maintenance with rituximab for 2 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B : no maintenance</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No further treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>rituximab 375 mg/m2 every 8 weeks for 24 months (12 injections) or control with no treatment</description>
    <arm_group_label>A : rituximab maintenance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed follicular lymphoma grade 1, 2 or 3a.

          -  Patients previously untreated.

          -  Patients with at least one of the following symptoms requiring initiation of
             treatment:

               -  Bulky disease at study entry according to the GELF criteria: nodal or extranodal
                  mass &gt; 7cm in its greater diameter

               -  B symptoms

               -  Elevated serum LDH or beta2-microglobulin

               -  involvement of at least 3 nodal sites (each with a diameter greater than 3 cm)

               -  symptomatic splenic enlargement

               -  compressive syndrome

               -  pleural/peritoneal effusion

          -  Age must be &gt; 18 years.

          -  Performance status &lt; 2 on the ECOG scale (see appendix E).

          -  Adequate hematological function within 28 days prior to registration (unless those
             abnormalities are related to lymphoma extension), this includes:

               -  Hemoglobin ≥ 8.0 g/dl (5.0 mmol/L)

               -  Absolute neutrophil count (ANC) ≥ 1.5 109/L

               -  Platelet count ≥ 100 109/L

          -  Women are not breast feeding, are using effective contraception, are not pregnant and
             agree not to become pregnant during participation in the trial and during the 12
             months thereafter. Men agree not to father a child during participation in the trial
             and during the 12 months thereafter.

          -  Having previously signed a written informed consent form.

        Exclusion Criteria:

          -  Transformation to high-grade lymphoma (secondary to &quot;low-grade&quot; follicular lymphoma).

          -  Grade 3b follicular lymphoma.

          -  Presence or history of CNS disease (either CNS lymphoma or lymphomatous meningitis).

          -  Patients regularly taking corticosteroids during the last 4 weeks, unless administered
             at a dose equivalent to &lt; 20 mg/day prednisone.

          -  Patients with prior or concomitant malignancies except non-melanoma skin cancer or
             adequately treated in situ cervical cancer.

          -  Major surgery (excluding lymph node biopsy) within 28 days prior to registration.

          -  Poor renal function: Serum creatinine &gt; 2.0 mg/dl (197 μmol/L),

          -  Poor hepatic function: total bilirubin &gt; 2.0 mg/dl (34 μmol/L), AST (SGOT) &gt; 3 x the
             upper limit of normal unless these abnormalities are related to lymphoma.

          -  Known HIV infection or active HBV or HCV infection.

          -  Serious underlying medical conditions, which could impair the ability of the patient
             to participate in the trial (e.g. ongoing infection, uncontrolled diabetes mellitus,
             gastric ulcers, active autoimmune disease). Judgment is up to the investigator.

          -  Life expectancy &lt; 6 months

          -  Known sensitivity or allergy to murine products

          -  Treatment within a clinical trial within 30 days prior to trial entry

          -  Adult patient under tutelage.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles A Salles, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fundaleu Hospital</name>
      <address>
        <city>Buenos Aires</city>
        <zip>CP C1114AAN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Australian Leukemia and Lymphoma Group</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Université de Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe d'Etude des Lymphomes de l'adulte</name>
      <address>
        <city>Mont-Godinne</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Samaritano</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Santafé de Bogotá</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amtssygehuset i Herlev</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord</name>
      <address>
        <city>Bordeaux</city>
        <zip>33300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hématologie CHU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hématologie Adultes - Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie - Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre-Bénite cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Robert Debré</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hématologie CHU Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOVON</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Australia New Zealand Leukemia Lymphoma Group</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituo Nacional de Enfermedades Neoplasicas</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Spain</country>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.gela.org</url>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2005</study_first_submitted>
  <study_first_submitted_qc>August 31, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2005</study_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lymphoma</keyword>
  <keyword>follicular</keyword>
  <keyword>maintenance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

